Journal
CANCER TREATMENT REVIEWS
Volume 39, Issue 1, Pages 27-43Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2012.03.007
Keywords
Adjuvant; Chemotherapy; Disease-free survival; Immunotherapy; Molecularly targeted therapy; Neoplasms; Progression-free survival
Categories
Funding
- Merck
- BMS
- Novartis
- American Cancer Society
- Amgen
- Genentech
- National Cancer Institute [U10CA021115, P30 CA47904, P50CA121973]
- Merck Co. Inc.
- Whitehouse Station, NJ, USA
Ask authors/readers for more resources
Adjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and hormonal agents has shown a significant impact upon a variety of solid tumors. The principles that guide adjuvant therapy differ among various tumor types and specific modalities, but generally indicate a greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant therapy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies in current use for five major solid tumors highlights the rationale for current effective adjuvant therapy, and draws comparisons between the adjuvant regimens that have found application in solid tumors. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available